INTRAVENOUS ETIDRONATE IN THE MANAGEMENT OF MALIGNANT HYPERCALCEMIA
INTRAVENOUS ETIDRONATE IN THE MANAGEMENT OF MALIGNANT HYPERCALCEMIA
复制标题
DOI：
10.1001/archinte.145.3.449
复制
发表时间：
1985-01-01
影响因子：
--
通讯作者：
HICKS, R
中科院分区：
文献类型：
--
作者：
RYZEN, E;MARTODAM, RR;HICKS, R
高钙血症的治疗仍然是许多癌症患者管理中的常见问题。静脉注射依替膦酸二钠治疗26例恶性肿瘤患者的高钙血症。尽管有足够的水合作用和血清肌酐水平≤，但仍有持续性高钙血症的患者。1.5 mg/dl的剂量。给药包括连续1、2、3或4天静脉注射依替膦酸二钠，剂量为7.5 mg/kg/天，溶于250 ml生理盐水中，输注2小时。26名患者中有19名（73%）的血清Ca水平恢复到正常范围，平均反应时间为3 ± 1小时。2天在患有各种肿瘤的患者中观察到类似的反应率，包括乳腺癌，非小细胞肺癌和多发性骨髓瘤。静脉注射依替膦酸盐治疗恶性肿瘤患者的高钙血症是安全有效的。
The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. I.v. administered etidronate disodium was used as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level .ltoreq. 1.5 mg/dl were allowed on study. Treatment consisted of i.v. administered etidronate disodium at 7.5 mg/kg per day in 250 ml of saline infused over 2 h on 1, 2, 3, or 4 consecutive days. The serum Ca level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3 .+-. 2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non-small-cell lung cancer and multiple myeloma. I.v. administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.